We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalc... Gyre Therapeutics, Inc. is a clinical-stage biotechnology company. The Company is engaged in the research, development, manufacturing, and commercialization of drugs for organ fibrosis. It is primarily focused on the development and commercialization of F351 (Hydronidone) for the treatment of Nonalcoholic Steatohepatitis Treatment (NASH)-associated fibrosis. The Company is also advancing a diverse pipeline in the China through its indirect controlling interest in Gyre Pharmaceuticals, including ETUARY therapeutic expansions, F573, F528, and F230. The Company operates through two segments: Gyre Pharmaceuticals, and Gyre after the Contributions. The Gyre Pharmaceuticals has one major commercial drug product, ETUARY, and several product candidates in pre-clinical and clinical development. Gyre is a biopharmaceutical company focused on the development and commercialization of F351 for the treatment of non-alcoholic steatohepatitis-associated liver fibrosis in the United States. Show more
Ask ADVFN Intelligence (AI)
| Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | 1.11 | 14.0151515152 | 7.92 | 9.51 | 7.92 | 128698 | 8.72175223 | CS |
| 4 | -0.19 | -2.06073752711 | 9.22 | 9.51 | 6.11 | 189542 | 7.66306801 | CS |
| 12 | -2.47 | -21.4782608696 | 11.5 | 13.75 | 6.11 | 146981 | 9.23478079 | CS |
| 26 | -4.93 | -35.3151862464 | 13.96 | 19 | 6.11 | 122945 | 10.25688814 | CS |
| 52 | -6.96 | -43.5272045028 | 15.99 | 19 | 6.11 | 91327 | 11.13419153 | CS |
| 156 | 2.03 | 29 | 7 | 30.4 | 5.88 | 92921 | 13.70750992 | CS |
| 260 | 2.03 | 29 | 7 | 30.4 | 5.88 | 92921 | 13.70750992 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
